EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
183 hedge funds and large institutions have $751M invested in Eagle Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 73 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
183
Holders Change
+3
Holders Change %
+1.67%
% of All Funds
4.02%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
17
Increased
57
Reduced
73
Closed
14
Calls
$4.24M
Puts
$1.99M
Net Calls
+$2.24M
Net Calls Change
+$4.87M
Top Buyers
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$12.3M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$3.24M |
| 3 |
MCM
Matarin Capital Management
New York
|
+$2.38M |
| 4 |
Renaissance Technologies
New York
|
+$2.05M |
| 5 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$2.05M |
Top Sellers
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$11.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.49M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$5.58M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.47M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.74M |
